Celltrion Considers US Manufacturing In Response To Trump Tariffs
Measures Also Include Securing US Inventory And Focus On Drug Substance Imports
Celltrion may consider establishing or acquiring US manufacturing facilities as well as securing more US inventory and shifting its focus onto drug substance rather than drug product imports, the Korean biosimilars giant has suggested, as it sought to assuage investor concerns over pharmaceutical tariffs announced by US president Donald Trump.
